Ophthalmic Devices Market To Stay In The Growth Quadrant In The Next 10 Years

Posted by Merin John on July 6th, 2021

A new-fangled norm is likely to be observed by the healthcare vertical going forward. In other words, the novel healthcare vertical normal for supply chains, tech projects, governing critical supplies, regulations, and resilience would be new frameworks built by inter-governmental and governmental agencies for data sharing and response to disease. The Ophthalmic Devices Market is there to move along the private and public collaborations and alliances.

According to a new market report published by Persistence Market Research “Global Market Study on Ophthalmic Devices: Asia to Witness Highest Growth by 2020,” the global ophthalmic devices market was valued at USD 29,171.5 million in 2014 and is expected to grow at a CAGR of 6.5% from 2014 to 2020, to reach an estimated value of USD 42,685.1 million in 2020.

Globally, the ophthalmic devices market is witnessing significant growth due to increasing prevalence of eye disorders, such as diabetic retinopathy and macular degeneration. In addition, growing global aging population, increasing government initiatives towards healthcare infrastructure in developing countries, and increasing incidence of lifestyle-associated diseases are also driving the growth of the market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/3188

Some of the major players in the global ophthalmic devices market:

•          Johnson & Johnson.
•          Essilor International.
•          Bausch & Lomb Incorporated.
•          Novartis AG.
•          HOYA CORPORATION.
•          Abbott Laboratories, Inc.

However, lack of awareness among people about eye disorders, poor primary healthcare infrastructure, and lack of insurance in developing countries hamper growth of the global ophthalmic devices market. In addition, eye diseases in children are also increasing due to the general lack of awareness.

The global ophthalmic devices market is anticipated to grow from an estimated USD 29,171.5 million in 2014 to USD 42,685.1 million in 2020 at a CAGR of 6.5% during the forecast period.

Age-related eye diseases, such as glaucoma, cataract, diabetic retinopathy, and age-related macular degeneration, are the leading causes of visual impairment and blindness in North America. According to the American Academy of Ophthalmology, approximately 22 million Americans aged 40 and above were affected by cataract and 2.3 million Americans were affected by glaucoma in 2011.

In Europe, increasing prevalence of chronic eye diseases among the rising aging population is becoming a challenge for the European healthcare system. In France, the number of age-related macular degeneration cases was 0.3 million in 2000 and it is anticipated to increase by 0.5 million in 2020.

However, glaucoma, cataract, and diabetic retinopathy are the major causes of blindness in Asia. Cataract can be held responsible for 50% to 80% of all cases of blindness in Southeast Asia. The prevalence of age-related macular degeneration is also increasing in Asia due to increase in life expectancy and rising incidence of diabetes among the younger population. As per the Centre for Eye Research Australia, prevalence of diabetic retinopathy among people ranged between 17% and 22% in India and 43.1% in rural China in 2012.